| 09:00 |
|
| 10:00 |
|
| 11:00 |
|
| 12:00 |
|
| 13:00 |
|
| 14:00 |
[14:00] IMBB - ICS Open Lecture
- Description:
- Paramet Summer School - Computational Sciences in Drug Discovery
Conor CAFFREY
Associate Professor
Center for Discovery and Innovation in Parasitic Diseases
Department of Pathology, University of California San Francisco
Title: "Drug discovery and development for global parasitic diseases at UCSF".
Tuesday, July 1st 2014 @ 14:00 (note that the lecture starts exactly at 14:00)
Seminar Room 1, FORTH's bldg
Information: Inga Siden-Kiamos (inga@imbb.forth.gr), Ioannis Tsamardinos (tsamard@ics.forth.gr)
Abstract:
Founded in 2001, the CDIPD at UCSF supports anti-parasitic drug discovery and development via target validation, hit identification and hit-to-lead optimization. Disease priorities include trypanosomatid and helminth diseases and I’ll provide context for some of the cross-disciplinary discovery and development projects ongoing. I’ll then focus on the paradigm that cysteine proteases are essential and ‘druggable’ parasite proteins for the development of new drugs. I’ll give an example of one cysteine protease inhibitor’s journey through pre-clinical development as potential drug therapy for Chagas’ disease. Finally, I’ll emphasize how this particular program has spawned similar projects for other parasitic diseases.
--------------------------------------------------------------------------------
Short Bio:
Dr. Conor Caffrey is an Associate Adjunct Professor at the Department of Pathology at the School of Medicine, UCSF and a Senior Scientist at the Center for Discovery and Innovation in Parasitic Diseases (CDIPD), UCSF. He received his Ph.D. in Mol. & Biochemical Parasitology from the University College Dublin, Ireland.
A 20-year research track record reflects his strong interests in the basic (molecular, cell and chemical) and applied (diagnostics and drug development) biology of the tropical parasitic diseases, in particular, schistosomiasis, hookworm disease, African trypanosomiasis, and lately, cryptosporidiosis. Three broad themes underpin his research; (1) the identification and validation of protein targets (e.g., proteases and kinases) for potential drug development, (2) the pre-clinical and translational development of drugs, including the development and application of associated technologies (e.g., high-content and high-throughput screening platforms, RNA interference, C. elegans as a surrogate for screening anti-parasitics, protein expression, animal models of infection), and (3) development of point-of care (POC) diagnostics.
|
| 15:00 |
|
| 16:00 |
|
| 17:00 |
|
| 18:00 |
|
| 19:00 |
|
| 20:00 |
|
| 21:00 |
|
July 2014
